https://scholars.lib.ntu.edu.tw/handle/123456789/626910
Title: | Microrna-486-5P Regulates Human Pulmonary Artery Smooth Muscle Cell Migration via Endothelin-1 | Authors: | TING-AN YEN HSIN-CHUNG HUANG EN-TING WU HENG-WEN CHOU HUNG-CHIEH CHOU CHIEN-YI CHEN SHU-CHIEN HUANG YIH-SHARNG CHEN FRANK LEIGH LU MEI-HWAN WU PO-NIEN TSAO CHING-CHIA WANG |
Keywords: | miR-486-5p; pulmonary arterial hypertension; pulmonary artery smooth muscle cells | Issue Date: | 8-Sep-2022 | Publisher: | MDPI | Journal Volume: | 23 | Journal Issue: | 18 | Source: | International journal of molecular sciences | Abstract: | Pulmonary arterial hypertension (PAH) is a fatal or life-threatening disorder characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance. Abnormal vascular remodeling, including the proliferation and phenotypic modulation of pulmonary artery smooth muscle cells (PASMCs), represents the most critical pathological change during PAH development. Previous studies showed that miR-486 could reduce apoptosis in different cells; however, the role of miR-486 in PAH development or HPASMC proliferation and migration remains unclear. After 6 h of hypoxia treatment, miR-486-5p was significantly upregulated in HPASMCs. We found that miR-486-5p could upregulate the expression and secretion of ET-1. Furthermore, transfection with a miR-486-5p mimic could induce HPASMC proliferation and migration. We also found that miRNA-486-5p could downregulate the expression of SMAD2 and the phosphorylation of SMAD3. According to previous studies, the loss of SMAD3 may play an important role in miRNA-486-5p-induced HPASMC proliferation. Although the role of miRNA-486-5p in PAH in in vivo models still requires further investigation and confirmation, our findings show the potential roles and effects of miR-486-5p during PAH development. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/626910 | ISSN: | 16616596 | DOI: | 10.3390/ijms231810400 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.